Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22090373 | 1.00 | HCRTR2 (0.39) | HCRTR2HCRTR1LTA4HPTGS2 | |
| SCHEMBL17784680 | 0.78 | FFAR1 (0.44) | — | |
| SCHEMBL22090409 | 0.77 | TDP1 (0.46) | LTA4H | |
| SCHEMBL18579706 | 0.77 | TDP1 (0.46) | LTA4H | |
| SCHEMBL22103541 | 0.76 | HCRTR2 (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL31192198 | 0.74 | GPR39 (0.43) | — | |
| SCHEMBL365267 | 0.74 | GPR39 (0.43) | — | |
| SCHEMBL3840511 | 0.74 | HRH1 (0.42) | — | |
| SCHEMBL15130036 | 0.73 | CTSL (0.45) | — | |
| SCHEMBL18580397 | 0.72 | LTA4H (0.51) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2020157474-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020120994-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885LTA4H 2653/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885LTA4H 2653/4885 |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | HCRTR2 5/4885HCRTR1 4/4885LTA4H 4311/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885LTA4H 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.